Alzheimer's Drug Promising Trial Results

Eisai and Biogen said they would apply for regulatory approval for a new Alzheimer’s drug following the results of a late-stage clinical trial that showed it slowed the rate at which the disease progresses. The phase-three trial had demonstrated that giving lecanemab, a monoclonal antibody treatment, to patients in the early stages of the disease reduced the rate of cognitive decline by 27 per cent compared with participants who received a placebo. https://www.ft.com/content/531636df-e937-41f5-81c1-5195fb4acd9b